1. Executive Summary |
2. Global Ovarian Cancer Treatment Market Introduction |
2.1. Global Ovarian Cancer Treatment Market – Taxonomy |
2.2. Global Ovarian Cancer Treatment Market –Definitions |
2.2.1. Drug Class |
2.2.2. Cancer Type |
2.2.3. Distribution Channel |
2.2.4. Region |
3. Global Ovarian Cancer Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Ovarian Cancer Treatment Market Dynamic Factors – Impact Analysis |
3.6. Ovarian Cancer Epidemiology |
3.7. Pipeline Analysis |
3.8. Target or Mechanism of Action Analysis |
3.9. Patient Journey |
3.10. Collaborations, Distribution Agreements, and Acquisitions |
4. Global Ovarian Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 |
4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Ovarian Cancer Treatment Market, By Drug Class, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1. Chemotherapeutic Agents |
5.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Targeted Therapy Drugs |
5.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Immune System Modulators |
5.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Hormones |
5.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Ovarian Cancer Treatment Market Forecast, By Cancer Type, 2017- 2021 and Forecast, 2022 – 2028 |
6.1. Epithelial Ovarian Tumor |
6.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Ovarian Germ Cell Tumor |
6.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Ovarian Stomatal Tumor |
6.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Primary Peritoneal Carcinoma |
6.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7. Global Ovarian Cancer Treatment Market, By Distribution Channel, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Ovarian Cancer Treatment Market Forecast, By Region, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Region, 2022 – 2028 |
9. North America Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Chemotherapeutic Agents |
9.1.2. Targeted Therapy Drugs |
9.1.3. Immune System Modulators |
9.1.4. Hormones |
9.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Epithelial Ovarian Tumor |
9.2.2. Ovarian Germ Cell Tumor |
9.2.3. Ovarian Stomatal Tumor |
9.2.4. Primary Peritoneal Carcinoma |
9.2.5. Others |
9.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Hospital Pharmacies |
9.3.2. Retail Pharmacies |
9.3.3. Others |
9.4. Country Analysis 2017 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. U.S. |
9.4.2. Canada |
9.5. North America Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, and Country, 2022 – 2028 |
9.6. North America Ovarian Cancer Treatment Market Dynamics – Trends |
10. Europe Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
10.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Chemotherapeutic Agents |
10.1.2. Targeted Therapy Drugs |
10.1.3. Immune System Modulators |
10.1.4. Hormones |
10.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Epithelial Ovarian Tumor |
10.2.2. Ovarian Germ Cell Tumor |
10.2.3. Ovarian Stomatal Tumor |
10.2.4. Primary Peritoneal Carcinoma |
10.2.5. Others |
10.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Hospital Pharmacies |
10.3.2. Retail Pharmacies |
10.3.3. Others |
10.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. Spain |
10.4.4. France |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Rest of Europe |
10.5. Europe Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel and Country, 2022 – 2028 |
10.6. Europe Ovarian Cancer Treatment Market Dynamics – Trends |
11. Asia-Pacific Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
11.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Chemotherapeutic Agents |
11.1.2. Targeted Therapy Drugs |
11.1.3. Immune System Modulators |
11.1.4. Hormones |
11.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Epithelial Ovarian Tumor |
11.2.2. Ovarian Germ Cell Tumor |
11.2.3. Ovarian Stomatal Tumor |
11.2.4. Primary Peritoneal Carcinoma |
11.2.5. Others |
11.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Hospital Pharmacies |
11.3.2. Retail Pharmacies |
11.3.3. Others |
11.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Japan |
11.4.2. China |
11.4.3. India |
11.4.4. Rest of Asia-Pacific |
11.5. Asia-Pacific Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2022 – 2028 |
11.6. Asia-Pacific Ovarian Cancer Treatment Market Dynamics – Trends |
12. Latin America Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
12.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Chemotherapeutic Agents |
12.1.2. Targeted Therapy Drugs |
12.1.3. Immune System Modulators |
12.1.4. Hormones |
12.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Epithelial Ovarian Tumor |
12.2.2. Ovarian Germ Cell Tumor |
12.2.3. Ovarian Stomatal Tumor |
12.2.4. Primary Peritoneal Carcinoma |
12.2.5. Others |
12.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Hospital Pharmacies |
12.3.2. Retail Pharmacies |
12.3.3. Others |
12.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Rest of Latin America |
12.5. Latin America Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2022 – 2028 |
12.6. Latin America Ovarian Cancer Treatment Market Dynamics – Trends |
13. Middle East and Africa Ovarian Cancer Treatment Market Analysis, 2017- 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
13.1. Drug Class Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Chemotherapeutic Agents |
13.1.2. Targeted Therapy Drugs |
13.1.3. Immune System Modulators |
13.1.4. Hormones |
13.2. Cancer Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Epithelial Ovarian Tumor |
13.2.2. Ovarian Germ Cell Tumor |
13.2.3. Ovarian Stomatal Tumor |
13.2.4. Primary Peritoneal Carcinoma |
13.2.5. Others |
13.3. Distribution Channel Type Analysis, 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Hospital Pharmacies |
13.3.2. Retail Pharmacies |
13.3.3. Others |
13.4. Country Analysis 2017- 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Saudi Arabia |
13.4.2. South Africa |
13.4.3. Rest of MEA |
13.5. MEA Ovarian Cancer Treatment Market – Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2022 – 2028 |
13.6. MEA Ovarian Cancer Treatment Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Eli Lilly and Company |
14.2.2. Johnson & Johnson Services, Inc. |
14.2.3. Kazia Therapeutics |
14.2.4. Aeterna Zentaris Inc |
14.2.5. GlaxoSmithKline plc |
14.2.6. F. Hoffmann-La Roche AG |
14.2.7. AbbVie Inc., |
14.2.8. Pfizer Inc., |
14.2.9. AstraZeneca plc |
14.2.10. Immunogen |
14.2.11. Novartis |
15. Research Methodology |
16. Key Assumptions and Acronyms |